DiaCarta Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 39

Employees

  • Latest Deal Type
  • Reverse Merger
  • (Cancelled)

  • Latest Deal Amount
  • $584M

  • Investors
  • 4

DiaCarta General Information

Description

Developer of detection tools designed for cancer diagnosis, therapy identification, and prognosis monitoring. The company's tools offer a range of cancer diagnostics and IVD products specialized in genomic testing for biomarkers and also offer clinical sample testing services apart from oncology along with COVID-19 testing services, enabling healthcare practitioners to provide improved care to patients.

Contact Information

Website
www.diacarta.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4385 Hopyard Road
  • Suite 100
  • Pleasanton, CA 94588
  • United States
+1 (800)
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Vertical(s)
Digital Health, HealthTech, Life Sciences, Oncology
Corporate Office
  • 4385 Hopyard Road
  • Suite 100
  • Pleasanton, CA 94588
  • United States
+1 (800)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DiaCarta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Reverse Merger 13-Oct-2022 $584M Cancelled Generating Revenue
4. Debt - PPP 14-May-2020 Completed Generating Revenue
3. Grant 17-Sep-2018 Completed Generating Revenue
2. Early Stage VC (Series B) 12-Feb-2018 $45M $53M Completed Generating Revenue
1. Early Stage VC (Series A) 09-Jan-2015 $8M $8M Completed Generating Revenue
To view DiaCarta’s complete valuation and funding history, request access »

DiaCarta Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of detection tools designed for cancer diagnosis, therapy identification, and prognosis monitoring. The compan
Laboratory Services (Healthcare)
Pleasanton, CA
39 As of 2025

Aliso Viejo, CA
 

Miami, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiaCarta Competitors (49)

One of DiaCarta’s 49 competitors is Ambry Genetics, a Formerly PE-Backed company based in Aliso Viejo, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ambry Genetics Formerly PE-Backed Aliso Viejo, CA
Igenomix Formerly PE-Backed Miami, FL
GeneCast Biotechnology Private Equity-Backed Wuxi, China
Biocept Formerly VC-backed San Diego, CA
Biodesix Formerly VC-backed Louisville, CO
You’re viewing 5 of 49 competitors. Get the full list »

DiaCarta Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 19

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

DiaCarta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4136229-A1 Sars-cov-2 test kit for rt-qpcr assays Pending 16-Apr-2020
CA-3175815-A1 Sars-cov-2 test kit for rt-qpcr assays Pending 16-Apr-2020
EP-4136229-A4 Sars-cov-2 test kit for rt-qpcr assays Pending 16-Apr-2020
EP-3494236-B1 Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence Active 05-Jan-2017
EP-3494236-A1 Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence Active 05-Jan-2017 C12Q1/6886
To view DiaCarta’s complete patent history, request access »

DiaCarta Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiaCarta Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
Fortune Fountain Capital PE/Buyout Minority
Global Healthcare Capital Real Estate Minority
BVCF Venture Capital Minority
To view DiaCarta’s complete investors history, request access »

DiaCarta Acquisitions (1)

DiaCarta’s most recent deal was a Merger/Acquisition with HH&L Acquisition for . The deal was made on 30-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
HH&L Acquisition 30-Jun-2023 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view DiaCarta’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

DiaCarta FAQs

  • When was DiaCarta founded?

    DiaCarta was founded in 2012.

  • Where is DiaCarta headquartered?

    DiaCarta is headquartered in Pleasanton, CA.

  • What is the size of DiaCarta?

    DiaCarta has 39 total employees.

  • What industry is DiaCarta in?

    DiaCarta’s primary industry is Laboratory Services (Healthcare).

  • Is DiaCarta a private or public company?

    DiaCarta is a Private company.

  • What is DiaCarta’s current revenue?

    The current revenue for DiaCarta is .

  • How much funding has DiaCarta raised over time?

    DiaCarta has raised $53M.

  • Who are DiaCarta’s investors?

    National Institutes of Health, Fortune Fountain Capital, Global Healthcare Capital, and BVCF have invested in DiaCarta.

  • Who are DiaCarta’s competitors?

    Ambry Genetics, Igenomix, GeneCast Biotechnology, Biocept, and Biodesix are some of the 49 competitors of DiaCarta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »